Daiichi Sankyo Expands MorphoSys Alliance To Include Antibodies For Infectious Disease
This article was originally published in PharmAsia News
Executive Summary
Japan's third-largest drug maker Daiichi Sankyo expanded its alliance with German biotech MorphoSys to include discovery and development of therapeutic antibodies for hospital-acquired infections. The earlier collaboration was focused solely on oncology
You may also be interested in...
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery
Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development